近一年中国人用疫苗进口情况统计图 数据来源：中国海关，智研咨询整理 相关报告：智研咨询发布的《2025-2031年中国人用疫苗行业竞争现状及投资决策建议报告》 根据中国海关数据显示：2025年8月中国人用疫苗进口数量为26吨，同比下降64.3%，进口金额为0.71亿 美元，同比下降76%，2025年8月中国人用疫苗出口数量为48.71吨，同比增长107.7%，出口金额为0.37 亿美元，同比增长50.1%。。 数据来源：中国海关，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 近一年中国人用疫苗出口情况统计图 ...

10月23日，康泰生物盘中下跌2.05%，截至10:56，报16.28元/股，成交8554.09万元，换手率0.58%，总 市值181.84亿元。 截至6月30日，康泰生物股东户数6.15万，较上期减少1.84%；人均流通股14634股，较上期增加3.48%。 2025年1月-6月，康泰生物实现营业收入13.92亿元，同比增长15.81%；归母净利润3753.27万元，同比减 少77.30%。 分红方面，康泰生物A股上市后累计派现17.65亿元。近三年，累计派现5.25亿元。 机构持仓方面，截止2025年6月30日，康泰生物十大流通股东中，易方达创业板ETF（159915）位居第 四大流通股东，持股1541.92万股，相比上期减少28.62万股。招商国证生物医药指数A（161726）位居 第六大流通股东，持股1037.57万股，相比上期减少70.88万股。南方中证500ETF（510500）位居第七大 流通股东，持股995.59万股，相比上期增加128.04万股。创新药（159992）位居第八大流通股东，持股 628.99万股，相比上期减少210.63万股。香港中央结算有限公司位居第十大流通股东，持股469. ...

相关报告：智研咨询发布的《2025-2031年中国人用疫苗行业竞争现状及投资决策建议报告》 近一年中国人用疫苗进口情况统计图 数据来源：中国海关，智研咨询整理 数据来源：中国海关，智研咨询整理 根据中国海关数据显示：2025年4月中国人用疫苗进口数量为19吨，同比下降85%，进口金额为0.39亿 美元，同比下降91.7%，2025年4月中国人用疫苗出口数量为33.15吨，同比增长1041%，出口金额为0.22 亿美元，同比增长81.3%。 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 近一年中国人用疫苗出口情况统计图 ...

转自：北京日报客户端 作为助推北京创新发展的"双发动机"产业之一，本市医药健康产业正加速向具有全球影响力的现代化医 药健康产业集群迈进。10月16日，记者从北京海关获悉，今年前8个月，北京地区医药健康产业相关商 品出口明显增长，医疗仪器及器械、医药材及药品分别出口58.3亿元、34.3亿元，分别增长21.5%、 6.8%。 科园信海（北京）医疗用品贸易有限公司助理总经理杨海宁对此深有体会，他介绍，该企业进口的疫苗 等货物需要保证2至6摄氏度冷链运输，对通关效率有很高要求。与传统进出区模式相比，智能卡口为其 节省了大量运输时间。据其介绍，今年1至8月，该企业医药产品入区规模达到277亿元，同比增长9%。 据悉，2025年前8个月，北京地区罕见病药品进口26.6亿元，增长59.1%，进口值位居全国之首。其中天 竺综保区进口罕见病药品25.6亿元，增长78.3%，占同期北京地区罕见病药品进口的96.4%。 来源：北京日报客户端 不仅如此，亦庄海关还试点属地远程查检，借助视频技术手段、设备，以远程视频查检代替现场查检， 提高了企业货物通关效率。"我们公司在大兴生物医药基地，距离亦庄海关24公里，现场查检距离远， 实行 ...

Core Viewpoint - 康泰生物's stock has experienced a decline in recent trading sessions, with a notable drop in both share price and net profit, indicating potential challenges in the company's financial performance and market perception [1][2]. Company Overview - 康泰生物, established on September 8, 1992, and listed on February 7, 2017, is located in Shenzhen, Guangdong Province. The company specializes in the research, production, and sales of human vaccines [1]. - The company's revenue composition includes 93.70% from non-immunization program vaccines, 3.71% from immunization program vaccines, and 2.59% from other sources [1]. Financial Performance - As of June 30, 2025, 康泰生物 reported a revenue of 1.392 billion yuan, representing a year-on-year growth of 15.81%. However, the net profit attributable to shareholders was 37.53 million yuan, reflecting a significant year-on-year decrease of 77.30% [2]. - The company has distributed a total of 1.765 billion yuan in dividends since its A-share listing, with 525 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of June 30, 2025, 康泰生物 had 61,500 shareholders, a decrease of 1.84% from the previous period. The average number of circulating shares per shareholder increased by 3.48% to 14,634 shares [2]. - The stock has seen a net outflow of 20.12 million yuan in principal funds, with significant selling pressure from large orders [1].

Core Viewpoint - Hualan Vaccine's stock experienced a decline of 1.24% on September 15, with a trading volume of 37.6 million yuan, indicating potential market volatility and investor sentiment shifts [1]. Financing and Margin Trading - On September 15, Hualan Vaccine had a financing buy-in amount of 4.11 million yuan and a financing repayment of 5.61 million yuan, resulting in a net financing outflow of 1.50 million yuan. The total financing and margin trading balance reached 115 million yuan, which is 1.04% of the circulating market value, indicating a relatively high level compared to the past year [1]. - The company had a margin trading activity on the same day, with 3,200 shares repaid and 400 shares sold short, amounting to a short sale value of 7,336 yuan. The remaining short selling volume was 22,100 shares, with a margin balance of 406,200 yuan, also reflecting a high level compared to the past year [1]. Financial Performance - For the first half of 2025, Hualan Vaccine reported a revenue of 59.96 million yuan, representing a year-on-year growth of 68.77%. However, the net profit attributable to shareholders decreased by 17.71% to 20.80 million yuan [2]. - Since its A-share listing, Hualan Vaccine has distributed a total of 680 million yuan in dividends, with 600 million yuan distributed over the past three years [3]. Shareholder Structure - As of August 10, the number of Hualan Vaccine shareholders decreased by 5.26% to 18,000, while the average circulating shares per person increased by 5.56% to 7,869 shares [2]. - As of June 30, 2025, the top ten circulating shareholders included various ETFs and investment funds, with notable changes in holdings among major shareholders, indicating shifts in institutional investment [3].

根据中国海关数据显示：2025年7月中国人用疫苗进口数量为23吨，同比下降80.7%，进口金额为0.79亿 美元，同比下降80%，2025年7月中国人用疫苗出口数量为9.52吨，同比增长41.7%，出口金额为0.15亿 美元，同比下降33.1%。 近一年中国人用疫苗进口情况统计图 近一年中国人用疫苗出口情况统计图 相关报告：智研咨询发布的《2025-2031年中国人用疫苗行业竞争现状及投资决策建议报告》 数据来源：中国海关，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 数据来源：中国海关，智研咨询整理 ...

9月4日，百克生物跌1.35%，截至发稿，报22.64元/股，成交9433.05万元，换手率1.00%，总市值93.65 亿元。百克生物股价已经连续8天下跌，区间累计跌幅10.69%。 资料显示，长春百克生物科技股份公司位于吉林省长春市朝阳区卓越大街138号，成立日期2004年3月4 日，上市日期2021年6月25日，公司主营业务涉及从事人用疫苗的研发、生产和销售。主营业务收入构 成为：销售商品100.00%。 从百克生物十大流通股东角度 数据显示，南方基金旗下1只基金位居百克生物十大流通股东。南方中证1000ETF（512100）二季度新 进十大流通股东，持有股数152.25万股，占流通股的比例为0.37%。根据测算，今日浮亏损失约47.2万 元。连续8天下跌期间浮亏损失412.61万元。 南方中证1000ETF（512100）基金经理为崔蕾。 截至发稿，崔蕾累计任职时间6年303天，现任基金资产总规模949.76亿元，任职期间最佳基金回报 136.9%， 任职期间最差基金回报-16.81%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、 ...

Core Viewpoint - 康泰生物's stock has shown fluctuations in recent trading sessions, with a notable increase in the year-to-date performance, while facing a decline in the short term [1][2]. Financial Performance - As of June 30, 康泰生物 reported a revenue of 1.392 billion yuan for the first half of 2025, representing a year-on-year growth of 15.81% [2]. - The net profit attributable to shareholders for the same period was 37.53 million yuan, which reflects a significant decrease of 77.30% compared to the previous year [2]. Stock Market Activity - On September 1, 康泰生物's stock price increased by 2.03%, reaching 19.09 yuan per share, with a trading volume of 74.48 million yuan and a turnover rate of 0.44% [1]. - The stock has experienced an 11.90% increase year-to-date, a 4.55% decline over the last five trading days, a 7.13% increase over the last 20 days, and a 25.84% increase over the last 60 days [1]. Shareholder Information - As of June 30, 康泰生物 had 61,500 shareholders, a decrease of 1.84% from the previous period, with an average of 14,634 circulating shares per shareholder, which is an increase of 3.48% [2][3]. - The company has distributed a total of 1.765 billion yuan in dividends since its A-share listing, with 525 million yuan distributed over the last three years [3]. Institutional Holdings - As of June 30, the top ten circulating shareholders of 康泰生物 include 易方达创业板ETF, which holds 15.42 million shares, a decrease of 286,200 shares from the previous period [3]. - Other notable shareholders include 招商国证生物医药指数A and 南方中证500ETF, with respective holdings of 10.38 million shares and 9.96 million shares, showing changes in their positions [3].

Core Viewpoint - The report provides a comprehensive overview of the fundraising activities and usage of funds by Liaoning Chengda Biological Co., Ltd. for the first half of 2025, highlighting the total amount raised, the allocation of funds, and the management of surplus funds [1][2][3]. Fundraising Overview - The total amount raised from the initial public offering (IPO) was RMB 4,581,500,000, with all funds received by October 25, 2021 [1]. - As of June 30, 2025, the balance in the fundraising account was RMB 434,929,298.11, after utilizing RMB 1,423,828,419.14 for various projects [1][2]. Fund Usage and Management - The company has invested a total of RMB 783,049,371.27 from the raised funds, with specific allocations for projects such as the human vaccine construction project and the biological product research and development base [1][3]. - The company has established a fundraising management system to ensure the proper use and efficiency of the funds, adhering to relevant laws and regulations [1][3]. Project Investment and Adjustments - The company has made adjustments to its fundraising projects, including the completion of the human vaccine construction project and the initiation of cash management for idle funds, allowing for investment in safe financial products [3][4]. - A total of RMB 69,000,000 from over-raised funds was permanently allocated to supplement working capital [4][5]. Financial Management Practices - The company has not used idle funds for temporary working capital supplementation during the reporting period, ensuring that all funds are allocated according to the planned projects [3][4]. - The company has also engaged in cash management practices, allowing for the investment of up to RMB 1.6 billion in safe financial products, with a focus on maintaining liquidity and security [3][4]. Compliance and Reporting - The company has complied with all relevant regulations regarding the use and disclosure of fundraising activities, ensuring transparency and accountability in its financial practices [4][5]. - No violations of fundraising usage and management regulations were reported during the period [4][5].